

Cabotegravir with rilpivirine for treating HIV-1

Information for the public

Published: 5 January 2022

www.nice.org.uk

Cabotegravir (Vocabria) with rilpivirine (Rekambys) is available on the NHS. It is a possible treatment for HIV-1 (the most common form of HIV) in adults:

- if the number of virus particles in their blood (the viral load) is lower than 50 per millilitre of blood while taking a stable dose of antiretrovirals and
- if they have tried treatments called non-nucleoside reverse transcriptase inhibitors or integrase inhibitors in the past, their condition has not become resistant to these, and their viral load has stayed low while taking them.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [UK-CAB](#) (HIV treatment advocates network), 0808 800 6013 (i-Base HIV treatment phoneline for treatment-specific questions)
- [National Aids Trust](#), 020 7814 6767

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4386-9